The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

All News

ADM to Acquire Deerland Probiotics & Enzymes
Biotics and Supplements

ADM to Acquire Deerland Probiotics & Enzymes

NOV 5, 2021
Probiotics : A Helping Hand Toward a Fitter Life
Biotics and Supplements

Probiotics : A Helping Hand Toward a Fitter Life

OCT 27, 2021
New study characterizes the gut virome
Pharma & Human Health

New study characterizes the gut virome

OCT 25, 2021
Solarea Bio Announces Licensing Agreement with ADM
Pharma & Human Health

Solarea Bio Announces Licensing Agreement with ADM

OCT 20, 2021
Axial Therapeutics Raises $37.25 Million in Series C Financing
Finance

Axial Therapeutics Raises $37.25 Million in Series C Financing

OCT 13, 2021
Framing the Narrative on CMC Development for Microbiome Therapeutics
Finance

Framing the Narrative on CMC Development for Microbiome Therapeutics

OCT 12, 2021
Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology
Pharma & Human Health

Intralytix Receives FDA Regulatory Clearance for Phage-Based Campylobacter Technology

OCT 11, 2021
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
Clinical & Manufacturing

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

OCT 5, 2021
Changing requirements for anaerobic culture equipment in microbiome research and product development
Pharma & Human Health

Changing requirements for anaerobic culture equipment in microbiome research and product development

OCT 5, 2021
L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes
Pharma & Human Health

L’Oréal Singapore and NTU Singapore set up joint lab hosted by SCELSE for deeper exploration of skin and scalp microbiomes

OCT 4, 2021
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

SEP 30, 2021